Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Choose from Biotech Images Pictures stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection ...

That candidate hits the same target as Elahere, the ADC that AbbVie acquired in its $10 billion takeover of ImmunoGen. Elahere received full FDA approval in ovarian cancer this year, but ...

The biotech company also reiterated its 2023 revenue forecast of $45M to $50M, excluding revenue generated by Elahere. Operating expenses are anticipated in the $350M to $365M range.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

Please use these images with photo credits as listed with each image. These images are sized for Web use. To download any of these files for use in print or web ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

The metaFlye assembler is designed to assemble DNA samples from microbial communities. With its help, it is possible to solve a wide range of fundamental and applied problems, among which is the ...

Just hours after the US Federal Reserve announced the first interest rate cut in four years, respiratory biotech Upstream Bio ...

And as targeting technology improves, large pharma companies are paying closer attention to the drug field and the many smaller biotechnology firms within ... chemistry and biomarker technology to ...